Navigation Links
Tailored Hepatitis C Therapy May Cut Treatment Time in Half
Date:9/14/2011

By Madonna Behen
HealthDay Reporter

WEDNESDAY, Sept. 14 (HealthDay News) -- Patients infected with hepatitis C virus who have an early favorable response to a new three-drug regimen can be cured of the disease in half the normal time, a new study says.

In the multinational study, researchers showed that tailoring patients' treatment regimen to their response to the drugs, which is known as response-guided therapy, enabled many patients to cut treatment time in half and still achieve the same cure rates.

The paper was published Sept. 15 in the New England Journal of Medicine.

"Patients treated with this regimen who clear virus from their blood by 4 weeks of therapy and who remain virus negative after 12 weeks of therapy can shorten total treatment time from 48 to 24 weeks and have an excellent chance of hepatitis C virus cure," said the study's lead author, Dr. Kenneth E. Sherman, Gould Professor of Medicine and director of the digestive diseases division at the University of Cincinnati College of Medicine in Ohio.

The regimen combines peginterferon and ribavirin, two drugs that have been the standard of care for hepatitis C for more than a decade, with a recently approved hepatitis C medication called telaprevir, which is in a class of medications known as protease inhibitors. Telaprevir and another protease inhibitor called boceprevir were approved by the U.S. Food and Drug Administration in May. The drugs work by blocking an enzyme that the hepatitis C virus needs in order to replicate itself.

For the study, Sherman and his colleagues studied 540 men and women with hepatitis C who hadn't previously been treated for the disease. All of the patients started therapy by receiving the three-drug regimen for 12 weeks, followed by just the peginterferon-ribavirin combination.

After 20 weeks, 322 patients who had an extended rapid virologic response (meaning they had undetectable levels of the virus by four weeks and remained virus-free after 12 weeks) were then randomly assigned to receive peginterferon-ribavirin for either four more weeks or 28 more weeks. At the end of the treatment period, 92 percent of the patients in the 24-week group had a sustained virologic response, meaning the virus remained cleared from their systems, compared with 88 percent of patients in the 48-week group.

Sherman said the patients who received a shorter course of treatment had lower rates of side effects and were less likely to stop treatment than those treated for 48 weeks. "In practice, this would be associated with lower treatment costs and better tolerability compared to use of 48-week treatment regimens," he said.

Another hepatitis specialist who was not involved in the study praised the findings.

"The standard medications for this disease have quite bothersome side effects, including flu-like symptoms, depression and hair loss, so if we're able to shorten the treatment duration by six months, that's worth quite a bit," said Dr. Nancy S. Reau, associate professor of medicine at the University of Chicago Medical Center.

Nearly 4 million Americans live with this difficult-to-manage disease, which can lead to liver cancer and is the number one cause of liver transplants in the United States. However, only about 25 percent of people are aware of their diagnosis because the virus can lurk in the body for years before patients begin to feel symptoms.

Many people become infected with the hepatitis C virus by sharing needles or other equipment to inject drugs. Sex with an infected person can also spread hepatitis C, and some patients contracted the virus through blood transfusions decades ago, before donor screening began in 1990.

Some patients responded so quickly to the regimen that they may have been able to shorten treatment time to fewer than 24 weeks, Sherman noted. "However, this was not investigated in this study, and would require other similarly designed studies to determine if this is true," he said.

The study was funded by two companies: Vertex Pharmaceuticals Inc., which markets telaprevir in North America under the brand name Incivek; and Tibotec, which markets the drug in Europe, Latin America and other parts of the world under the brand name Incivo.

More information

To learn more about hepatitis C, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: Kenneth E. Sherman, M.D., Ph.D., Gould Professor of Medicine, director, division of digestive diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio; Nancy S. Reau, M.D., associate professor of medicine, University of Chicago Medical Center, Chicago; Sept. 15, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tailored Therapy May Help More Stop Smoking
2. Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
3. PATH B -- a comprehensive support program for patients diagnosed with chronic hepatitis B
4. Hepatitis Rates Soar Among IV Drug Users, Study Finds
5. INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China
6. Hepatitis B vaccination for health care students lags behind recommendations
7. Hepatitis C is transmitted by unprotected sex between HIV-infected men
8. P7 protein resistance mutations identified; represent drug targets for hepatitis C virus
9. Stepped-up vaccine series for hepatitis B is effective during pregnancy
10. New Drug Effectively Treats Hepatitis C
11. NEJM study: New drug represents breakthrough in treatment of hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tailored Hepatitis C Therapy May Cut Treatment Time in Half
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... 29, 2016 , ... Mobility Designed is redefining mobility with their patent ... M+D Crutch evenly distributes body weight from the elbow to the forearm. In ... crutches than with other crutches. , Co-founders Max and Liliana Younger were inspired to ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
Breaking Medicine Technology: